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age, sex, presence of type 2 diabetes mellitus, Kt/V, nPCR and TLC. The
association of a GNRI Z 90 with a TLC Z 1500/mm3 seemed to exclude the
occurring of complications with moderate reliability.
Conclusion: These results demonstrate that the GNRI may be a signiﬁcant
predictor of mortality in Korean hemodialysis patients. However, the use of
TLC might improve the evaluation of nutritional risk and the identiﬁcation of
patients at risk of malnutrition.Figure 1. Total lymphocytes count and 120-
month survival of hemodialysis patients. In both groups, survival rate during
the follow-up period was similar. (life table analysis, P ¼ 0.500).
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NATURAL CORRECTION OF HYPERURICEMIA, NOT BY ALLOPURINOL,
COULD SLOW DOWN THE PROGRESSION OF RENAL DISEASE IN THE
PATIENT WITH CHRONIC KIDNEY DISEASE STAGE 3
Kyung Sun Park, Jai Won Chang
University of Ulsan College of Medicine, Asan Medical Center, Seoul, South
Korea
Purpose: Correction of hyperuricemia can slow down the progression of
renal disease in animal study. However, there is limited data regarding the
effect of lowering serum uric acid in patients with hyperuricemic chronic
kidney disease (CKD) stage 3 (estimated GFR [eGFR] 30-60 mL/min).
Methods: We retrospectively investigated 100 patients (age 56.179.9
years, M:F¼79:21) with hyperuricemia (serum uric acid 7.970.9 mg/dL)
and CKD stage 3 (eGFR 52.077.0 mL/min) 10 years ago. First, to evaluate
the effect of allopurinol on the progression of renal disease, 23 patients
who have taken allopurinol were compared with the randomly selected 23
patients according to the level of serum uric acid and eGFR as a control
group among the other 77 patients who have never received allopurinol.
Second, to clarify the effect of lowering serum uric acid by diet on renal
disease progression, these 77 patients were divided into 2 groups by
decreased amount of serum uric acid during 10 years and compared each
other (group 141.0 mg/dL vs. group 2 o1.0 mg/dL).
Results: First, although serum uric acid levels were signiﬁcantly decreased
(8.571.0 to 6.671.2 mg/dL, po0.001) in subjects treated with allopurinol,
the change of eGFR was not signiﬁcant (48.878.6 to 44.5718.5 mL/min,
p¼0.230). In control group, serum uric acid was also decreased (8.271.0 to
7.371.6 mg/dL, p¼0.025) but eGFR did not change signiﬁcantly (49.078.7
to 50.3720.2 mL/min, p¼0.726). Second, eGFR increased signiﬁcantly
(54.076.0 to 63.1718.0 mL/min, p¼0.002) in the group 1 whereas eGFR
decreased (51.976.4 to 46.1715.6 mL/min, p¼0.008) in the group 2 after
10 years. In the multivariate linear regression analysis in the entire cohort
(n¼100), age (p¼0.023), change of serum creatinine (p¼0.001), and change
of serum uric acid (po0.001) were found to be signiﬁcant factors that
inﬂuence the change of eGFR during study period.
Conclusions: We identiﬁed the protective effect of lowering serum uric acid
against progression of renal disease in patients with CKD stage 3. However,
allopurinol itself did not have such beneﬁcial effect.
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WHAT TO EAT. THE TERAPEUTIC AND DIETETIC COMPLIANCE OF
PATIENTS ON PERITONEAL DIALYSIS.
F. Pasticci, A. Selvi, M.T. Benedetto, A. Zuccal a
U.O.C. Nefrologia and Dialisi-AULS n 2 dell’Umbria
U.O.C. Nefrologia and Dialisi -Imola
Nutrition education is important for patients on peritoneal dialysis. Yet,
despite initial nutrition training and monthly reinforcements during
follow-up visits, phosphorus control remains unsatisfactory. For this reason
a meeting with an external renal dietician open to patients and their
relatives was organized. Biographical data and average phosphorus levels
for the 3 months prior to the meeting are shown in Table.1
Patients 11 (6 F - 5 M)
Age (years) 63 (47-81)
Time on Dialysis (months) 72 (6-348)
Body Mass Index (kg/m2) 25.8 (22.3-32.4)
Phosphorous mg/dl (average of 3 months) 5.95 (3.9-8.2)
After a lecture delivered by the centre’s nephrologist, a questionnaire on
phosphorus control was compiled by the participants. The renal dietician
then explained how to: control dietary phosphorous intake, properly use
chelating agents, reduce phosphorous in cooking and make smart food
choices. A trained chef then demonstrated how to cook some regional
recipes speciﬁcally reworked to reduce their phosphorous content without
sacriﬁcing taste. Participants then veriﬁed that the recipes were indeed
appetizing. At this point, the same questionnaire given at the start of the
meeting was re-given. From this, an improvement in the understanding of
phosphorus control was seen. For example, in response to the question
‘‘Who is responsible for controlling phosphorus?’’ the percentage of
patients correctly answering ‘‘the patient’’ rose from 55% before the
meeting to 91% after the meeting. To successfully manage kidney disease
patients and their relatives need to understand how to best control for
phosphorous and this can only be done through continuous nutrition
education. The Authors are waiting on the results of phosphorus levels for
the next 3 months. The Authors would like to thank Baxter Healthcare for
its organizational support.
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DOES WEIGHT LOSS ADD VALUE TO BLOOD PRESSURE CONTROL AMONG
PATIENTS WITH DIABETIC KIDNEY DISEASE?
Uptal Patel, Shelby Reed
Duke Clinical Research Institute, Durham, North Carolina.
Obesity is an independent risk factor for development and progression of
diabetic kidney disease (DKD). Whether weight loss provides any additional
beneﬁt beyond blood pressure (BP) control is unclear. To simulate a trial, we
used the Archimedes model, a person-speciﬁc simulation model including
detailed representations of physiology, diseases, and health care systems. Our
population-based sample represented individuals diagnosed with type
2 diabetes and DKD drawn from 1999-2006 cohorts of NHANES. Simulations
were generated to estimate costs and health outcomes across time for
3 treatment strategies: (1) standard of care (STD); (2) blood pressure control
(BP); and (3) BP combined with 5% weight loss (BPWT). BP control represents
3.5%&6% reductions for those with SBP4130 and SBP4140, respectively. Over
a 20y time horizon, discounted costs for the STD group were $165,261 with
discounted quality adjusted life-years (QALYs) of 5.89. With BP estimated at
$30/month, the incremental cost-effectiveness ratio (ICER) was $26,626/QALY
compared to STD. With BPWT at $50/month, the ICER was $31,773 compared
to STD. Even with varying intervention costs and durations (Figure), the ICERs
remained favorable, especially for the BPWT group.In conclusion, weight loss in
addition to BP control appears to provide favorable value, particularly over
moderate time horizons.
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